Alkhalaf Hamad A, Alhamied Nawaf A, Alqahtani Abdulmajeed M, Alsomali Faisal A, Alrasheed Malek A, Alhafi Mohammed M, Alqirnas Muhannad Q, Alhamied Fawaz A, Albaqami Faris M, Almosa Abdulaziz S, Othman Fatmah, Naeem Mohammed
Department of Pediatrics, King Abdullah Specialized Children Hospital, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, SAU.
King Abdullah International Medical Research Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, SAU.
Cureus. 2023 Jan 2;15(1):e33267. doi: 10.7759/cureus.33267. eCollection 2023 Jan.
Introduction Septic shock remains a leading cause of mortality in pediatric patients. Corticosteroids have been used in the management of sepsis and septic shock, but there is conflicting evidence on the potential benefit of corticosteroid therapy. This study assessed the risk of mortality and length of stay in the pediatric intensive care unit (PICU) among pediatric patients admitted with a septic shock diagnosis. Method A retrospective cohort study was conducted among pediatric patients (up to 14 years old) admitted with a septic shock diagnosis to the PICU of King Abdullah Specialist Children's Hospital in Riyadh from January 2016 to December 2021. The clinical outcomes of patients receiving corticosteroid therapy were compared to those of control patients who were not given corticosteroids. Electronic medical records provided clinical data, severity scores, and the management given for each patient. The patients were followed up from the date of sepsis diagnosis to hospital discharge. Proportional hazard ratios (HRs) were calculated to compare the risk of mortality, length of PICU stay, and length of hospital stay. Results A total of 182 pediatric patients were included in the study, and 86 (47%) received corticosteroid therapy. The median age of the study population was 15 months (interquartile range [IQR]: 2-72 months). Compared to the controls, the patients who received corticosteroids had a higher total Sequential Organ Failure Assessment (SOFA) score (mean±SD: 5.5±3 vs. 7.1±3.3, respectively; p <0.01) and required more ventilation support (72% vs. 28%, respectively) and the use of inotropes and vasopressors (74% vs. 34% and 32% vs. 6%, respectively). In-hospital mortality did not significantly differ between the groups (adjusted HR: 2.66; 95% confidence interval [CI]: 0.66-10.28). Those patients who received corticosteroids had 42% less risk of staying in the PICU for over six days than those not receiving steroids (HR: 0.35; 95% CI: 0.13-0.98) Conclusion After adjusting for baseline characteristics, severity scores, and medical intervention, no association was found between receiving corticosteroids and mortality (p=0.492). Furthermore, patients who received corticosteroids had less risk of a prolonged stay in the PICU than those who did not.
引言
脓毒性休克仍然是儿科患者死亡的主要原因。皮质类固醇已被用于脓毒症和脓毒性休克的治疗,但关于皮质类固醇治疗潜在益处的证据存在矛盾。本研究评估了脓毒性休克诊断入院的儿科患者在儿科重症监护病房(PICU)的死亡风险和住院时间。
方法
对2016年1月至2021年12月在利雅得阿卜杜拉国王专科医院PICU因脓毒性休克诊断入院的儿科患者(14岁及以下)进行了一项回顾性队列研究。将接受皮质类固醇治疗的患者的临床结局与未接受皮质类固醇治疗的对照患者进行比较。电子病历提供了临床数据、严重程度评分以及给予每位患者的治疗措施。从脓毒症诊断日期至出院对患者进行随访。计算比例风险比(HR)以比较死亡风险、PICU住院时间和住院时间。
结果
本研究共纳入182例儿科患者,其中86例(47%)接受了皮质类固醇治疗。研究人群的中位年龄为15个月(四分位间距[IQR]:2 - 72个月)。与对照组相比,接受皮质类固醇治疗的患者序贯器官衰竭评估(SOFA)总分更高(分别为均值±标准差:5.5±3对7.1±3.3;p<0.01),需要更多的通气支持(分别为72%对28%)以及使用血管活性药物(分别为74%对34%和32%对6%)。两组的院内死亡率无显著差异(调整后HR:2.66;95%置信区间[CI]:0.66 - 10.28)。接受皮质类固醇治疗的患者在PICU停留超过6天的风险比未接受类固醇治疗的患者低42%(HR:0.35;95%CI:0.13 - 0.98)
结论
在调整基线特征、严重程度评分和医疗干预后,未发现接受皮质类固醇治疗与死亡率之间存在关联(p = 0.492)。此外,接受皮质类固醇治疗的患者在PICU长时间停留的风险低于未接受治疗的患者。